New hope for lung transplant patients facing chronic rejection
NCT ID NCT03283007
First seen Nov 01, 2025 · Last updated Apr 20, 2026 · Updated 22 times
Summary
This study tested whether the drug nintedanib could slow the decline of lung function in transplant patients who develop chronic rejection. Fifty-eight lung transplant recipients with early-stage rejection were randomly assigned to receive either nintedanib or a placebo pill for six months. The main goal was to see if the drug could better preserve how much air patients could forcefully exhale compared to the dummy treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG-TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Foch Hospital
Suresnes, 92150, France
Conditions
Explore the condition pages connected to this study.